云南省103例皮肤科医生对生物制剂认知及应用情况的问卷调查

中华养生保健 ›› 2023, Vol. 41 ›› Issue (11): 5-9.

云南省103例皮肤科医生对生物制剂认知及应用情况的问卷调查

赵悦, 张洪卫, 廖承成^*, 和增萍, 杨洋, 杨月皎

云南省中医医院（云南中医药大学第一附属医院）皮肤科,云南昆明,650021

出版日期:2023-06-01 发布日期:2023-05-25
通讯作者: ^*廖承成,E-mail：liaochengcheng@163.com。
作者简介:赵悦（1998—）,女,白族,籍贯：云南省大理市,硕士研究生在读,研究方向：皮肤病的防治研究。
基金资助:
云南省冯素英专家工作站（202105AF150035）; 云南省中医医院卓越人才项目[云中附党字（2021）5号]

Questionnaire Survey of 103 Dermatologists' Cognition and Application of Biological Agents in Yunnan Province

ZHAO Yue, ZHANG Hong-wei, LIAO Cheng-cheng^*, HE Zeng-ping, YANG Yang, YANG Yue-jiao

Department of Dermatology, Yunnan Hospital of Traditional Chinese Medicine（The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine）, Kunming Yunnan 650021, China

Online:2023-06-01 Published:2023-05-25

摘要/Abstract

摘要： 目的了解云南省皮肤科医生关于生物制剂的认知及应用等情况。方法在2022年4月~2022年6月制订并向云南省皮肤科医生发放电子问卷进行匿名调查。结果回收有效问卷103份,结果显示医生对生物制剂的知晓率为99.03%,使用率为72.82%,患者使用后的显效率为98.67%,并存在医生群体的认知水平及应用能力参差不齐、容易忽视患者的健康及经济等需求、医疗机构及社会政策的保障体系有待完善、中西医结合治疗理念仍需加强、未来还需大样本多中心的流行病学研究等情况。结论云南省皮肤科医生对生物制剂的认知及应用已有一定发展,但仍存在不足,未来还需制定全面的行业和地区标准,规范皮肤科医生的专科培训,努力使生物制剂朝精准医疗的方向发展。

关键词: 云南, 皮肤科医生, 生物制剂, 问卷调查

Abstract: Objective To understand the cognition and application of biological agents among dermatologists in Yunnan province. Methods From April to June, 2022, an electronic questionnaire was developed and distributed to dermatologists in Yunnan Province for anonymous investigation. Results 103 valid questionnaires were collected. The results showed that the doctor's awareness rate of biological agents was 99.03%, the utilization rate was 72.82%, and the remarkable efficiency rate of patients after use was 98.67%. Besides, the doctor's cognitive level and application ability were uneven, and it was easy to ignore the needs of patients' health, economy and care. The guarantee system of medical institutions and social policies needed to be improved, the concept of integrated traditional Chinese and western medicine treatment still needed to be strengthened, and large samples and multi-centers were needed in the future. Conclusion Yunnan dermatologists' cognition and application of biological agents have developed to some extent, but there are still some shortcomings. In the future, it is necessary to formulate comprehensive industry and regional standards, standardize the specialist training of dermatologists, and strive to make biological agents develop in the direction of precision medicine.

Key words: Yunnan, dermatologist, biological agents, questionnaire survey

中图分类号:

R751.05

赵悦, 张洪卫, 廖承成, 和增萍, 杨洋, 杨月皎. 云南省103例皮肤科医生对生物制剂认知及应用情况的问卷调查[J]. 中华养生保健, 2023, 41(11): 5-9.

ZHAO Yue, ZHANG Hong-wei, LIAO Cheng-cheng, HE Zeng-ping, YANG Yang, YANG Yue-jiao. Questionnaire Survey of 103 Dermatologists' Cognition and Application of Biological Agents in Yunnan Province[J]. ZHONGHUA YANGSHENG BAOJIAN, 2023, 41(11): 5-9.

参考文献

[1] 叶瑞贤,梁晓冬,邓婕,等.生物靶向制剂在皮肤科的应用进展[J].皮肤性病诊疗学杂志,2018,25(6):368-372.
[2] 宋群先,李建伟.生物制剂时代中西医结合治疗银屑病的思路与探讨[J].中医研究,2022,35(6):12-17.
[3] SMITH C H, YIU Z Z N, BALE T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020:a rapid update[J]. Br J Dermatol,2020,183(4):628-637.
[4] 史玉玲. 英国《皮肤科医生协会银屑病生物制剂治疗指南》(2020版)解读[J].诊断学理论与实践,2021,20(1):37-42.
[5] 中华医学会皮肤性病学分会,中国医生协会皮肤科医生分会,中国中西医结合学会皮肤性病专业委员会.中国银屑病生物治疗专家共识(2019)[J].中华皮肤科杂志,2019,52(12):863-871.
[6] 中华医学会皮肤性病学分会,中国医生协会皮肤科医生分会,中国中西医结合学会皮肤性病专业委员会.中国银屑病生物制剂治疗指南(2021)[J].中华皮肤科杂志,2021,54(12):1033-1047.
[7] 韩笑,栗玉珍.作用于细胞因子的生物制剂在银屑病治疗中的研究进展[J].医学综述,2022,28(9):1724-1729.
[8] SUBEDI S, GONG Y, CHEN Y, et al.Infliximab and biosimilar infliximab in psoriasis: Efficacy, loss of efficacy, and adverse events[J]. Drug Des Devel Ther,2019,13: 2491-2502.
[9] 苗华丽,闫明,高霞.类风湿关节炎患者生物制剂注射意愿及影响因素的调查与分析[J].山西职工医学院学报,2016,26(5):65-67.
[10] 田涛,王洪伟,张雪.特应性皮炎的生物制剂靶向治疗[J].临床皮肤科杂志,2022,51(3):190-192.
[11] 严檬,余纪芬.皮肤科患者服药依从性调查与管理措施[J].中医药管理杂志,2018,26(11):13-14.
[12] 张琼翔,朱希聪.皮肤科患者用药依从性改变调查与管理建议[J].中医药管理杂志,2017,25(19):27-28.
[13] 奚鑫. 皮肤科患者用药依从性改变调查与管理建议[J].名医,2020,11(13):107-108.
[14] 石艾秀,曹双林.分子靶向抗肿瘤药物皮肤不良反应研究进展[J].中国麻风皮肤病杂志,2021,37(9):605-609.
[15] 张翰林,舒畅,晋红中.生物制剂治疗银屑病的研究进展[J].中国科学:生命科学,2021,51(8):1050-1059.
[16] 吴晓丹,刘一凡,李娟.药占比管制下过度医疗行为演化研究[J].系统工程理论与实践,2019,39(12):3163-3174.
[17] 沈洪,朱磊,张露.生物制剂背景下克罗恩病中西医结合治疗策略探讨[J].南京中医药大学学报,2022,38(8):739-742.
中华医学会,中华医学会杂志社,中华医学会皮肤性病学分会, 等.银屑病基层诊疗指南(2022年)[J]. 中华全科医师杂志,2022,21(8):705-714.
[19] 张学军. 加强银屑病的基层规范化诊疗[J].中华全科医师杂志,2022,21(8):701-704.
[20] 黄丹,陈崑.银屑病相关流行病学调查进展[J].诊断学理论与实践,2021,20(1):48-52.